- Norwegian Haugan dazzles in men's World Cup slalom win
- Arsenal's Saka out for 'many weeks' with hamstring injury
- Mali singer Traore child custody case postponed
- France mourns Mayotte victims amid uncertainy over government
- UK economy stagnant in third quarter in fresh setback
- Sweden says China denied request for prosecutors to probe ship linked to cut undersea cables
- African players in Europe: Salah leads Golden Boot race after brace
- Global stock markets edge higher as US inflation eases rate fears
- German far-right AfD to march in city hit by Christmas market attack
- Ireland centre Henshaw signs IRFU contract extension
- Bangladesh launches $5bn graft probe into Hasina's family
- US probes China chip industry on 'anticompetitive' concerns
- Biden commutes sentences for 37 of 40 federal death row inmates
- Clock ticks down on France government nomination
- 'Devastated' Australian tennis star Purcell provisionally suspended for doping
- Mozambique on edge as judges rule on disputed election
- Mobile cinema brings Tunisians big screen experience
- Philippines says to acquire US Typhon missile system
- Honda and Nissan to launch merger talks
- Police arrest suspect who set woman on fire in New York subway
- China vows 'cooperation' over ship linked to severed Baltic Sea cables
- Australian tennis star Purcell provisionally suspended for doping
- Asian markets track Wall St rally as US inflation eases rate fears
- Luxury Western goods line Russian stores, three years into sanctions
- Wallace and Gromit return with comic warning about AI dystopia
- Philippine military says will acquire US Typhon missile system
- Afghan bread, the humble centrepiece of every meal
- Honda and Nissan expected to begin merger talks
- 'Draconian' Vietnam internet law heightens free speech fears
- Israeli women mobilise against ultra-Orthodox military exemptions
- Asian markets track Wall St rally as US inflation eases rate worries
- Tens of thousands protest in Serbian capital over fatal train station accident
- Trump vows to 'stop transgender lunacy' as a top priority
- Daniels throws five TDs as Commanders down Eagles, Lions and Vikings win
- 'Who's next?': Misinformation and online threats after US CEO slaying
- Only 12 trucks delivered food, water in North Gaza Governorate since October: Oxfam
- BluSky Carbon Announces $1 Million Convertible Debenture Financing
- Abasca Resources Closes Non-Brokered Private Placement of $3.2 Million
- Greenlane Appoints Rob Shields as Chief Growth Officer
- American Resources Corporation's ReElement Technologies Produces Greater than 99.5% Pure Terbium For National Defense Supply Chain
- Beyond Work Unveils Next-Generation Memory-Augmented AI Agent (MATRIX) for Enterprise Document Intelligence
- Northern Superior Announces ONGold's Completion of Monument Bay and Domain Projects Acquisition in Manitoba
- ARIA Cybersecurity Solutions Partners with UFT to Protect Water Treatment Facilities from Dangerous Cyberattacks
- Clear Start Tax Named 2024 Orange County Register’s Top Workplaces for Exceptional Tax Resolution Service and Workplace Culture
- Ensysce Biosciences Regains Full Compliance with Nasdaq
- Tortoise Capital Completes Merger of Tortoise Power and Energy Infrastructure Fund, Inc. (NYSE: TPZ), Tortoise Pipeline & Energy Fund, Inc. (NYSE: TTP), and Tortoise Energy Independence Fund, Inc. (NYSE: NDP) and Conversion to Actively Managed ETF
- Tortoise Capital Completes Merger of Tortoise Energy Infrastructure Corp. (NYSE: TYG) and Tortoise Midstream Energy Fund, Inc. (NYSE: NTG)
- Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease
- Datametrex Cancels RSUS
- South Star Battery Metals Announces Upsize of Non-Brokered Private Placement to Raise Up to US$3.20M, Extends Closing and Amended and Restated Stream Agreement
Nanomerics Reports First Volunteers Dosed in the OC134 SUNLIGHT Trial
., a private speciality pharmaceutical company today announced that dosing had commenced in its OC134 Phase I trial - the SUNLIGHT trial. Following approval in November 2024 from the UK Medicinal and Healthcare Products Regulatory Agency (MHRA), dosing of the first volunteers with both Nanomerics' MET eye drops and OC134 eye drops, took place this week. The clinical testing of Nanomerics' eye drop assets is being done by Quotient Sciences at its Nottingham, UK facility.
OC134 is an eye drop medicine candidate indicated for the topical treatment of moderate to severe allergic conjunctivitis, a condition for which a suitable non-steroidal topical ocular treatment, does not currently exist.
OC134 is powered by Nanomerics' Molecular Envelope Technology (MET), a non-irritant ocular penetration enhancer. Nanomerics' MET is a platform ocular penetration enhancer, that has been shown in preclinical studies to increase the penetration of active pharmaceutical ingredients (APIs) into the front of the eye; increasing ocular deposition up to 18-fold, when compared to conventional formulations. In these preclinical studies, Nanomerics' MET also demonstrated the delivery of APIs to the retina from eye drops. Nanomerics has a pipeline of ocular assets that may now be tested in clinical studies and ultimately launched for the benefit of patients.
Professor Andreas G. Schätzlein, Nanomerics' Chief Executive Officer said,
"Nanomerics has been working towards this day for many years and we are very proud that we have been able to commence clinical testing with our lead ophthalmology asset. This day marks the culmination of many years of hard work with excellent team members, collaborators and advisors. This is a major value creation step for the company and we are now poised to develop medicinal products powered by our world beating non-irritant ocular penetration enhancer - Nanomerics' Molecular Envelope Technology (MET)."
Dr Nand Singh, Medical Director at Quotient Sciences commented,
"We are excited to begin clinical testing at our Nottingham, UK clinic for Nanomerics' OC134 Phase 1 Sunlight trial. This marks an important step forward in developing advanced treatments for moderate to severe allergic conjunctivitis."
About Nanomerics
Nanomerics Ltd is a speciality pharmaceutical company with state-of-the-art laboratories based in London, UK. Nanomerics was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Nanomerics' proprietary technology is based on world leading know-how and scientific leadership in polymer nanotechnology. Nanomerics creates uniquely differentiated, patented pharmaceutical assets, underpinned by high quality science. For example, the company's Molecular Envelope Technology (MET) is a unique patented biocompatible polymer that delivers a step change in target tissue bioavailability. The founding scientists, Professor Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Pharmaceutical product candidates in development include the eye drops: OC134 for the treatment of moderate to severe allergic conjunctivitis, OC137 for the treatment of retinal diseases and OC135 for the treatment of glaucoma. For more information, please visit www.nanomerics.com.
For press enquiries contact:
Pedro Margarido
Head of Operations, Nanomerics Ltd.
[email protected]
About Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programmes and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast, because humanity needs novel therapeutic solutions, fast. Quotient Sciences has been recognized as a multi-year winner of the CRO Leadership Awards in 2021, 2022, and 2024 and of the CDMO Leadership Awards in 2023. For more information, visit quotientsciences.com.
For press enquiries, contact:
Erica Fearnley
Executive Director, Strategic Marketing at Quotient Sciences
[email protected]
Rachael Heath
Senior PR Manager at RaMarketing & PR
[email protected]
SOURCE: Nanomerics Ltd
O.Johnson--AMWN